Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gliptin versus a sulphonylurea as add-on to metformin.

× No keyword cloud information.

9 in total

1. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.

Authors: T Haak; T Meinicke; R Jones; S Weber; M von Eynatten; H-J Woerle
Journal: Int J Clin Pract Date: 2013-10-09 Impact factor: 2.503

Review 2. Tight glycemic control and cardiovascular effects in type 2 diabetic patients.

Authors: Latha Subramanya Moodahadu; Ruchi Dhall; Abdul Hamid Zargar; Sudhakar Bangera; Lalitha Ramani; Ramesh Katipally
Journal: Heart Views Date: 2014 Oct-Dec

3. Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study.

Authors: Ahmed Ak Hassoun; Md Faruque Pathan; Rita C Medlej; Monira Alarouj; Inass Shaltout; Manoj S Chawla; Ditte Knap; Julius A Vaz
Journal: Diabetes Metab Syndr Obes Date: 2016-07-26 Impact factor: 3.168

4. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.

Authors: Yaeko Kondo; Norio Harada; Akihiro Hamasaki; Shizuka Kaneko; Koichiro Yasuda; Eiichi Ogawa; Shin-Ichi Harashima; Hiroko Yoneda; Yoshihito Fujita; Norikazu Kitano; Yoshio Nakamura; Fujio Matsuo; Megumi Shinji; Shiro Hinotsu; Takeo Nakayama; Nobuya Inagaki
Journal: Diabetol Metab Syndr Date: 2016-02-27 Impact factor: 3.320

5. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.

Authors: György Jermendy; Zoltán Kiss; György Rokszin; Zsolt Abonyi-Tóth; István Wittmann; Péter Kempler
Journal: Diabetes Ther Date: 2018-08-17 Impact factor: 2.945

6. Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus.

Authors: Elisabetta Bigagli; Cristina Luceri; Ilaria Dicembrini; Lorenzo Tatti; Francesca Scavone; Lisa Giovannelli; Edoardo Mannucci; Maura Lodovici
Journal: Antioxidants (Basel) Date: 2020-03-11

Gliptin versus a sulphonylurea as add-on to metformin.

1. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.

Review 2. Tight glycemic control and cardiovascular effects in type 2 diabetic patients.

3. Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study.

4. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.

5. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.

6. Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus.

Review 7. Metformin: A Prospective Alternative for the Treatment of Chronic Pain.

8. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes.

Review 9. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.